TABLE 3.

Adverse event profile of AK0529 compared with placebo.

	AK0529 (N = 49), n (%)	Placebo (N = 24), n (%)	Total (N = 73), n (%)
Subjects with any AEs	25 (51.0%)	10 (41.7%)	35 (47.9%)
Subjects with any TEAEs	24 (49.0%)	10 (41.7%)	34 (46.6%)
Subjects with any drug related TEAEs	3 (6.1%) a	0	3 (4.1%)
Subjects with any serious TEAEs	2 (4.1%) b	0	2 (2.7%)
Subjects with any TEAEs induced withdrawal	0	0	0
Subjects with any grade ≥3 TEAEs	2 (4.1%) c	1 (4.2%) d	3 (4.1%)
Subjects with any TEAEs leading to death	0	0	0

Abbreviations: AEs, adverse events; SAEs, serious adverse events; TEAEs, treatment‐emergent adverse events.

^a One case each of increased aspartate aminotransferase, increased transaminases, hyperkalemia.

^b Two cases of unrelated pneumonia.

^c One case of pneumonia, classified as SAE; one case of elevated transaminase.

^d One case of pneumonia.